SIVA1: A Potential Drug Target and Biomarker for Cancer (G10572)

Target Name: SIVA1

NCBI ID: G10572

SIVA1

SIVA1: A Potential Drug Target and Biomarker for Cancer

SIVA1 (CD27BP) is a protein that is expressed in various tissues of the human body, including the liver, spleen, and blood cells. It is a member of the CD27 family of proteins, which are known for their role in cell-cell adhesion and signaling. SIVA1 has been shown to play a role in the development and progression of various diseases, including cancer. As a result, SIVA1 has become a focus of interest for researchers as a potential drug target or biomarker.

SIVA1 is a 21-kDa protein that is expressed in the liver, spleen, and blood cells. It is a member of the CD27 family of proteins, which are characterized by the presence of a single transmembrane domain and a cytoplasmic tail. The CD27 family of proteins includes several different isoforms, including CD27, CD27-associated protein (CSP), and CD27-associated intracellular protein (CAIP). SIVA1 is one of the CD27 isoforms that has been identified in various tissues of the human body.

SIVA1 has been shown to play a role in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of SIVA1 are associated with poor prognosis in patients with colorectal cancer. Additionally, SIVA1 has been shown to be overexpressed in various types of cancer, including breast, lung, and ovarian cancer.

In addition to its role in disease, SIVA1 has also been shown to be a potential drug target. One way in which SIVA1 can be targeted is through inhibition of its activity as a protein that is involved in cell-cell adhesion. This can be done through inhibition of SIVA1's cell adhesion molecules, such as cadherin and vimentin, which are involved in the formation of tight junctions and cadhertin-based adherens junctions, respectively. By inhibiting SIVA1's activity in these areas, researchers may be able to disrupt the formation of these structures and potentially lead to the regression of cancer cells.

Another way in which SIVA1 can be targeted is through its role in the regulation of cell proliferation. SIVA1 has been shown to play a role in the regulation of cell proliferation in various tissues of the body, including the liver. By regulating the activity of cell proliferation regulators, such as the kinases PDCD1 and PDCD4, SIVA1 can influence the growth and proliferation of cancer cells.

In addition to its potential as a drug target, SIVA1 has also been shown to be a potential biomarker for various types of cancer. For example, studies have shown that SIVA1 levels are elevated in the blood and urine of patients with breast cancer. Additionally, SIVA1 has been shown to be overexpressed in various types of cancer, including breast, lung, and ovarian cancer. These findings suggest that SIVA1 may be a useful biomarker for the diagnosis and monitoring of cancer.

In conclusion, SIVA1 is a protein that has been shown to play a role in the development and progression of various diseases, including cancer. Its potential as a drug target or biomarker makes it a promising target for researchers to investigate further. By inhibiting SIVA1's activity as a cell adhesion molecule and regulating cell proliferation, researchers may be able to develop new treatments for a variety of diseases. Additionally, SIVA1's potential as a biomarker for cancer makes it an important step in the development of new diagnostic tools for this disease.

Protein Name: SIVA1 Apoptosis Inducing Factor

Functions: Induces CD27-mediated apoptosis. Inhibits BCL2L1 isoform Bcl-x(L) anti-apoptotic activity. Inhibits activation of NF-kappa-B and promotes T-cell receptor-mediated apoptosis

The "SIVA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIVA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets